Semnur Pharmaceuticals, Inc. (SMNR): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$5.87M

Year ended 2025-12-31

2022-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$5.87M	n/m	2026-02-27, From 2025-01-01
2024-12-31	-$4.89M	n/m	2026-02-27, From 2024-01-01
2023-12-31	-$632.8K	n/m	2025-04-02, From 2023-01-01
2022-12-31	-$426.1K	n/a	2024-04-01, From 2022-01-05

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Semnur Pharmaceuticals, Inc. (SMNR)	2025-12-31	-$5.87M	n/m
Aspire Biopharma Holdings, Inc. (ASBP)	2025-12-31	-$4.92M	n/m
Accustem Sciences Inc. (ACUT)	2025-12-31	-$850.4K	n/m
NeuroSense Therapeutics Ltd. (NRSN)	2025-12-31	-$7.67M	n/m
Ocean Biomedical, Inc. (OCEA)	2024-12-31	-$4.18M	n/m
Alzamend Neuro, Inc. (ALZN)	2026-04-30	-$8.07M	n/m
Inhibitor Therapeutics, Inc. (INTI)	2025-12-31	-$3.23M	n/m
Vaccinex, Inc. (VCNX)	2024-12-31	-$16.19M	n/m
Provectus Biopharmaceuticals, Inc. (PVCT)	2025-12-31	-$3.33M	n/m

Compare SMNR, ASBP, ACUT, NRSN side by side · Screen every company in Pharmaceutical Preparations ↗